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Abstract 
Isochromosome of the long arm of chromosome 7 is 
a known chromosomal abnormality in hematological 
malignancies that may be found in patients with 
Shwachman-Diamond syndrome, hepatosplenic T-
cell lymphoma and acute lymphoblastic leukemia. In 
myeloid malignancies, i(7)(q10) may be found in 
acute myeloid leukemias and chronic 
myeloproliferative disorders, either as a solely 
anomaly or more frequently as a secondary anomaly 
associated with other additional anomalies. 
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Figure 1.  Partial karyotypes showing i(7)(q10) (A). Fluorescence in situ hybridization with Vysis LSI D7S486 
(7q31) SpectrumOrange/ Vysis CEP 7 SpectrumGreen probe (Downers Grove, IL) hybridizing to bands 7q11 and 
7q31, demonstrated 3 copies of the long arm of chromosome 7 (red signal) (B). Hybridization with Vysis whole 
chromosome 7 probe showing the normal and the i(7)(q10) chromosome (green) (C). 
Clinics and pathology 
Disease 
Chronic myeloproliferative disorders, 
myelodysplastic syndromes, and acute myeloid 
leukemias (AML) 
Epidemiology 
14 cases (10 males and 4 females, aged 5 to 67 years) 
were diagnosed with various chronic 
myeloproliferative disorders: 6 myelodysplastic 
syndrome (MDS) (Ref. in Table 1.), 6 chronic 
myeloid leukemia (CML), 1 essential 
thrombocythemia (ET) and 1 idiopathic 
i(7)(q10) in myeloid malignancies  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(10) 436 
 
myelofibrosis (IF) (Table 1).  
 
There were 40 AML patients, with prevalence of 
acute megakaryoblastic leukemia (AML-M7) cases, 
diagnosed in 14 (Ref. in Table 2.), among them 8 
diagnosed in patients with Down's syndrome (DS). 
The remaining AML cases were: 5 acute 
undifferentiated leukemia (AML-M0), 2 acute 
myeloblastic leukemia without maturation (FAB 
type M1), 4 acute myeloblastic leukemia with 
maturation (FAB type M2), 2 acute promyelocytic 
leukemia (FAB type M3), 2 acute myelomonocytic 
leukemia (FAB type M4), 3 acute monoblastic 
leukemia (FAB type M5), 2 acute erythroleukemia 
(FAB type M6) and 6 AML cases (Table 2).  
 
35 male and 19 female patients aged 0 to 86 years 
(median 12 years); 25 patients were children aged 0 
to 12 years ( median 1 years), among them 14 
Down's syndrome patients aged 0 to 12 years 
(median 1 year); adult cases were 19 to 86 years old 
(median 55 years).  
 
 
Table 1. i(7)(q10) in chronic myeloproliferative disorders and myelodysplastic syndrome
 
  Sex/Age Disease Karyotype 
1 F/67 RARS 46,XX,i(7)(q10)  
2 F/50 RARS 46,XX,i(7)(q10)/46,idem,i(17)(q10) 
3 M CML 46,XY,i(7)(q10),t(9;22)(q34;q11) 




5 M/6 MDS 46,XY,i(7)(q10) 
6 M/5 MDS 46,XY,i(7)(q10)/46,XY,del(20)(q11)      Shwachman-Diamond syndrome 
7 M/55 CML 46,XY,i(7)(q10),t(9;22)(q34;q11) 
8 M CML 46,XX,i(7)(q10),t(9;22)(q34;q11) 
9 M/48 CML 46,XY,i(7)(q10),t(9;22)(q34;q11) 
10 M/67 ET 48,XY,+8,+21/46,XY,i(7)(q10) 
11 M/49 CML 92,XXYY,i(7)(q10)x2,t(9;22)(q34;q11)x2  
12 F/42 MDS 46,XX,i(7)(q10)/46,idem,del(11)(q14)      Fanconi anemia 
13 F/53 IF 48,XX,del(5)(q13q31),i(7)(q10),+8,add(11)(p15)      PDGFRB 
14 M/10 CML 46,XY,t(9;14)(q33;q32),t(9;22)(q34;q11)/46,idem,i(7)(q10)  
1. Labal de Vinuesa et al., 1987; 2. Larripa et al., 1987; 3. Werner et al., 1991; 4. Tien et al., 1994; 5. Dror et al., 1998; 6. Dror 
et al., 1998; 7. Nakayama et al., 1999; 8. Marktel et al., 2003; 9. Tanaka et al., 2004; 10. Ohyashiki et al., 2008; 11. Fabarius 
et al., 2011; 12. Quentin et al., 2011; 13. Arefi et al., 2012; 14. Nadal et al., 2012 
Abbreviations: M, male; F, female; RARS, refractory anemia with ringed sideroblasts; CML, chronic myeloid leukemia; RAEB, 
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1 F/12 AML-M2 46,XX,i(7)(q10) 
2 M/19 AML-M4 46,XY,i(7)(q10) 
3 M/0 AML-M2 47,XY,i(7)(q10),+21c 
4 F/40 AML-M2 46,XX,i(7)(q10) / 46,XX,del(1)(q?),i(7)(q10) 
5 M/2 AML-M5 47,XY,i(7)(q10),der(14)t(1;14)(q23;q32),+21 
6 F/12 AML-M1 45,XX,-4,i(7)(q10),-11,add(13)(q?),del(20)(q?),+21c 
7 M AML-M7 46,XY,inv(3)(q21q26),i(7)(q10) 
8 M/31 AML-M1 47,XY,+X,i(7)(q10),t(11;19)(q23;p13) 
9 M/1 AML-M7 47,XY,der(4)t(1;4)(q32;q34),i(7)(q10),+21c/47,idem,der(7)i(7)(q10)del(7)(q11q21) 
10 F/7 AML 46,XX,t(11;18)(q23;p11)/46,idem,i(7)(q10) 
11 M/72 AML-M7 46,XY,inv(3),i(7)(q10) 
12 F/2 AML-M7 47,XX,i(7)(q10),+der(11)t(11;14)(p13;q11),-14,+21/47,idem,dup(1)(q21q24) 
13 M/1 AML-M7 47,XY,der(5)t(1;5)(q31;p14),+21c/47,idem,i(7)(q10) 
14 M/3 AML-M5 47,XY,i(7)(q10),+21c 
15 F/0 AML-M5  46,XX,i(7)(q10) 
16 F/61 AML-M2 46,XX,inv(4)(p?q?),i(7)(q10) 






18 M AML 
69,XY,-X,+1,+i(2)(q10),add(3)(q?),-5,del(5)(q?),-7,i(7)(q10),-8,del(11)(q14q23),-12,-13,-15,-16,-
17,+19 
19 F/69 AML 46,XX,del(5)(q13q31)/46,idem,i(7)(p10),i(7)(q10)/46,idem,del(12)(p11) 
20 M AML 48,XY,i(7)(q10),+8,dup(8)(p11p23)x2,+21 
21 M/43 APL 46,XY,i(7)(q10),t(11;17)(q23;q21) 
22 M/76 AML-M7 47,XY,+1,add(3)(q21),i(7)(q10),+der(12)t(12;21)(p11;q?)x2,-21 
23 M/11 AML-M1 46,XY,t(10;17)(p15;q21)/46,idem,i(7)(q10) 
24 F/1 AML-M7 47,XX,der(4)t(1;4)(q23;p15),inv(9)(p11q13)c,+21c/47,XX,i(7)(q10),inv(9)c,+21c 
25 F/1 AML-M7 47,XX,+2,i(7)(q10) 
26 M/71 AML-M6 
51-54,X,del(X),+1,del(5),+del(5),+6,i(7)(q10),+8,t(11;19),t(12;15)(p13;q22),t(13;14)c,+14,+15, 
r(19),+20,+20,+21 
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27 M/49 AML-M0 46,XY,i(7)(q10) 
28 F/45 APL 48-49,XX,+X,+del(5)(q13q33)x2,i(7)(q10),ins(17;15)(q12;q22q22)x2,der(22)t(1;22)(q22;q10) 
29 M/1 AML-M7 47,XY,i(7)(q10),+21c 
30 F/67 AML-M4 88-92,XXXX,-7,i(7)(q10)x2,-9,del(9)(q31),+1-3mar,inc 
31 M/0 AML-M7 47,XY,i(7)(q10),+21c 
32 M/1 AML-M0 
47,XY,i(7)(q10),+21c / 
47,XY,+1,der(1;8)(q10;q10),i(7)(q10),add(11)(q25),del(16)(q12),add(18)(p11),+21c/94,idemx2 
33 M/1 AML-M7 47,XY,der(3)t(3;3)(p25;p10),i(7)(q10),der(17)t(1;17)(q25;q25),+21c 
34 M/5 AML-M0 48,XY,der(1)add(1)(p32)dup(1)(q21q26),del(3)(q21q26),i(7)(q10),del(16)(q22q24),+21,+21c 
35 M AML-M7 47,XY,add(5)(p15),i(7)(q10),add(11)(p11),+21 
36 M/56 AML-M1 46,XY,add(1)(p36),i(7)(q10) 
37 M/1 AML-M6 47,XY,i(7)(q10),+21c 
38 F/1 AML-M7 46,XX,i(7)(q10),der(9)t(1;9)(q25;q34),-16,add(19)(q13),+21c 
39 F/71 AML 46,XX,t(3;8)(q26;q24)/46,idem,del(7)(p11p15)/45,idem,i(7)(q10) 
40 M/1 AML-M7 47,XY,?del(11)(q23q23),+21/47,idem,i(7)(q10) 
1-2. Labal de Vinuesa et al., 1987; 3. Pui et  al., 1987; 4. Iurlo et al., 1989; 5. Hayashi et al., 1990; 6. Bunin et al.,  
1991; 7. Levy et al., 1994; 8. Finke et al., 1994; 9. Martinez-Climent et al.,  1995; 10. Roulston et al., 1995; 11. 
Secker-Walker et al., 1995; 12.Shikano et  al., 1995; 13-14. Creutzig et al., 1996; 15.Cimino et al., 1997; 16. El-
Rifai  et al., 1997; 17. Andreasson et al., 1998; 18. Archimbaud et al., 1998; 19. Streubel  et al., 1998; 20. Raimondi 
et al., 1999; 21. Grimwade et al., 2000; 22. Alvarez  et al.,2001; 23. Shah et al., 2001; 24. Strehl et al., 2001; 25. 
Yamada et al.,  2001; 26. Cigudosa et al 2003; 27. Roumier et al., 2003; 28. Tchinda et al.,  2004; 29. Chang et al., 
2005; 30. Bene et al., 2006; 31. Massey et al., 2006;  32. Wong et al., 2006; 33. Hama et al., 2008; 34. Hasle et 
al.,2008; 35. Radtke  et al., 2009; 36. Duhoux et al., 2011; 37. Lundin et al., 2012; 38. Yoshida et  al., 2013; 39. 
Xu et al., 2014; 40. Ono et al., 2015.  
Abbreviations: M, male; F, female; AML-M2., acute  myeloblastic leukemia with maturation; AML-M4, acute 
myelomonocytic leukemia; AML-M5;  acute monoblastic leukemia; AML-M1, acute myeloblastic leukemia 
without  maturation; AML-M7; acute megakaryoblastic leukemia; AML, acute myeloid  leukemia; APL, acute 




May depend on chronic versus acute disease and the 
presence of other karyotypic anomalies; likely 
unfavorable in association with disease progression 
and/or complex karyotypes. 
Cytogenetics 
Additional anomalies 
Sole anomaly in 2 MDS (Labal de Vinuesa et al., 
1987; Dror et al., 1998) and 10 AML patients (Labal 
de Vinuesa et al., 1987; Pui et al., 1987; Iurlo et al., 
1989; Creutzig et al., 1996; Cimino et al., 1997; 
Roumier et al., 2003; Chang et al., 2005; Massey et 
al., 2006; Lundin et al., 2012), 5 of them were DS 
patients with +21 (Pui et al., 1987; Creutzig et al., 
1996; Chang et al., 2005; Massey et al., 2006; 
Lundin et al., 2012). Found as a sole addition 
anomaly to t(9;22)  in 5 out of 6 CML patients 
(Werner et al., 1991; Nakayama et al., 1999; Marktel 
et al., 2003; Tanaka et al., 2004; Fabarius et al., 
2011) and in association with t(9;14)(q33;q32) in 1 
(Nadal et al., 2012). Associated with i(17)(q10) in 1 
MDS (Larripa et al., 1987), del(20)(q11)  in patient 
with MDS and Shwachman-Diamond syndrome  
(Dror et al., 1998), del(11)(q14) in MDS in a Fanconi 
anemia patient (Quentin et al., 2011),  
del(5)(q13q31), PDGFRB rearrangement  and +8  in 
idiopathic myelofibrosis (Arefi et al., 2012) and 
found in a sideline with +8, +21  in the ET case 
(Ohyashiki et al., 2008). Highly complex anomalies 
in 1 MDS (Tien et al., 1994). Among the AML cases, 
associated with inv(3)  in 2 (Levy et al., 1994; 
i(7)(q10) in myeloid malignancies  
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Secker-Walker et al., 1995), t(11;19)(q23;p13) in 1 
(Finke et al., 1994), t(11;18)(q23;p11) in 1 (Roulston 
et al., 1995) and t(11;17)(q23;q21)  in the AML-M3 
patient (Grimwade et al., 2000). Various limited 
anomalies in 8 (Creutzig et al., 1996;  El-Rifai et al., 
1997; Streubel et al., 1998; Raimondi et al., 1999; 
Shah et al., 2001; Yamada et al., 2001; Duhoux et 
al., 2011; Ono et al., 2015) and higly complex 
karyotypes in the remaing AML patients. 




Isochromosome of the long arm of chromosome 7 is 
a nonrandom chromosome anomaly in myeloid 
malignancies including acute myeloid leukemias, 
chronic myeloid leukemia, myelodysplastic 
syndromes and myeloproliferative neoplasms. 
Usually observed as an additional anomaly or is part 
of complex karyotypes, indicating involvement of 
genes from chromosome 7 in disease progression. 
i(7)(q10) results in a loss of the short arm (7p) and 
duplication of the long arm (7q) leading to a single 
copy of 7p and three copies of 7q resulting in 
genomic unbalances. The gain of genes on 7q as a 
result of isochromosome formation may play a 
significant role in the pathogenesis while   loss of 
tumor suppressor gene or genes from 7p might be a 
required cooperating event. 
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